--- canonical_name: Butea superba alternate_names: Red Kwao Krua, Red Kwao Khrua, Red Gwow Kreur, Kwao Krua Daeng, Elephant Root canonical_topic: Butea superba to Improve Testosterone short_topic_lc: butea_superba_testosterone creation_date: 2026-0810-0225 creator_ai_fullname: Grok 4 --- # Butea superba to Improve Testosterone
Evidence Review created on 08/10/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4 **Also known as:** Red Kwao Krua, Red Kwao Khrua, Red Gwow Kreur, Kwao Krua Daeng, Elephant Root ## Motivation *Butea superba* is a climbing legume whose tuberous root has been used for generations in Thai traditional medicine as a male vitality and sexual-performance herb, often marketed as the counterpart to white Kwao Krua (*Pueraria mirifica*). Its roots contain plant compounds that can interact with hormone receptors and with pathways that control blood flow in erectile tissue. Interest among health-optimizing adults stems from small human trials on erectile function, a single case report of elevated levels of a potent testosterone byproduct after use, and animal work suggesting weak male-hormone–like effects at some doses — alongside animal data showing reduced blood testosterone at high doses. Product quality is a recurring concern: one comparative study could not reproduce positive erectile results after the first batch was found to contain an undeclared prescription-style ingredient. This review examines whether *Butea superba* improves testosterone and related male-hormone status in humans, what the supporting and conflicting evidence shows for sexual function and safety, and what practical dosing, monitoring, and sourcing considerations emerge from the published record. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading Curated high-level sources that introduce *Butea superba*, its traditional use, and the limited clinical evidence base relevant to testosterone and male sexual function. * [Clinical trial of Butea superba, an alternative herbal treatment for erectile dysfunction](https://pubmed.ncbi.nlm.nih.gov/12937809/) - Cherdshewasart & Nimsakul, 2003 The only randomized double-blind human trial of crude *B. superba* tuber for erectile dysfunction; reports International Index of Erectile Function-5 (IIEF-5, a five-item erectile-function questionnaire) outcomes and documents that blood testosterone did not change significantly over three months. * [The use of Butea superba (Roxb.) compared to sildenafil for treating erectile dysfunction](https://pubmed.ncbi.nlm.nih.gov/19624593/) - Cortés-González et al., 2010 Open-label then double-blind comparison with sildenafil that initially favored a commercial *B. superba* product; the effect vanished with a second batch and the supplier later confirmed phosphodiesterase-5 (PDE5, an enzyme that breaks down cyclic guanosine monophosphate (cGMP, a vessel-dilating cell-signaling molecule) and is the target of drugs such as sildenafil) inhibitor adulteration — essential context for any claim based on commercial products. * [Rise of herbal and traditional medicine in erectile dysfunction management](https://pubmed.ncbi.nlm.nih.gov/21948222/) - Ho & Tan, 2011 Narrative overview of herbal erectile-dysfunction agents that places *B. superba* among the few botanicals with any human data and notes that published human trials are not robust. * [Hyperandrogenemia due to ingestion of Butea superba](https://pubmed.ncbi.nlm.nih.gov/22629537/) - Chaiyasit & Wiwanitkit, 2012 Single-patient case report of elevated dihydrotestosterone (DHT, a potent testosterone metabolite) that normalized after stopping a local *B. superba* capsule — the only published human signal of measurable androgen elevation. * [Butea superba Roxb. enhances penile erection in rats](https://pubmed.ncbi.nlm.nih.gov/16619349/) - Tocharus et al., 2006 Key preclinical paper linking root-core extract to increased intracavernous pressure (pressure inside the penile erectile chambers) and cyclic guanosine monophosphate / cyclic adenosine monophosphate (cGMP/cAMP, related cell-signaling molecules that support smooth-muscle relaxation) pathway enhancement — the main mechanistic rationale for erectile rather than endocrine claims. No dedicated content from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, or Lifespan.io was found that discusses *Butea superba* by name in substantial depth; the list above is therefore limited to peer-reviewed clinical, narrative, and mechanistic sources. ## Grokipedia * [Butea superba](https://grokipedia.com/page/Butea_superba) Broad botanical and ethnopharmacology overview covering taxonomy, traditional Thai/Indian use as a male rejuvenative tonic, tuberous-root chemistry (flavonoids, sterols), and modern interest in androgenic and anti-estrogenic animal findings. ## Examine * [Butea superba](https://examine.com/supplements/butea-superba/) Evidence-graded Examine page summarizing two human trials (about 70 participants), Grade D evidence for male sexual dysfunction outcomes, traditional 100–250 mg dosing ranges, unknown identity of the primary androgenic bioactives, and safety caveats at high doses. ## ConsumerLab No dedicated ConsumerLab product review for *Butea superba* was found as of August 10, 2026. Mentions appear only within multi-ingredient sexual-enhancer recalls and a general sexual-enhancer category review. ## Systematic Reviews No systematic reviews or meta-analyses for *Butea superba* were found on PubMed as of August 10, 2026. ## Mechanism of Action Proposed actions fall into two partly independent domains: erectile tissue blood-flow pathways and weak, dose-dependent effects on the hypothalamic–pituitary–gonadal axis (HPG axis, the brain–testis hormone loop that sets testosterone production). **Erectile / vascular pathway.** Ethanol extracts of dried root core increase intracavernous pressure (blood pressure within the erectile chambers of the penis) in aged and diabetic rats and relax cavernosal smooth muscle (the muscle lining those chambers). Effects are additive with cyclic guanosine monophosphate (cGMP, a signaling molecule that dilates blood vessels in erectile tissue) and with isobutyl-methylxanthine (IBMX, a broad phosphodiesterase inhibitor), consistent with partial phosphodiesterase inhibition and enhanced cAMP/cGMP signaling rather than a classical steroid hormone action. **Phytochemistry.** Tuberous roots contain isoflavones including genistein, daidzein, biochanin A, formononetin, and prunetin, plus pterocarpans (a class of plant phenolic compounds, e.g., medicarpin) and phytosterols (β-sitosterol, campesterol, stigmasterol). These compounds can bind estrogen receptors (ERα/ERβ) with low relative potency versus estradiol, show anti-estrogenic activity in some yeast and MCF-7 (a human breast-cancer cell line used to test estrogenic activity) models, and in isolation (daidzein plus genistein) have raised serum testosterone and sperm parameters in mice — a synergy not yet shown for whole-plant human use. **Androgen-axis findings (animals).** At moderate oral doses in intact male rats, whole-plant powder often leaves serum testosterone, luteinizing hormone (LH, the pituitary signal that drives testicular testosterone), and follicle-stimulating hormone (FSH, the pituitary signal for sperm production) unchanged while modestly increasing accessory sex-organ weight at the highest tested dose — consistent with a weak androgen-like peripheral signal that may need endogenous testosterone. High subchronic doses (150–200 mg/kg body weight/day for 90 days) lowered serum testosterone dose-dependently without a matching LH rise, and raised liver enzymes. In orchidectomized rats (testes surgically removed), higher doses reduced LH, again suggesting weak androgen-receptor or feedback activity. In female rats, tuber powder produced uterine growth and anti-estrogenic LH effects. **Human endocrine signal.** In the 2003 Thai erectile-dysfunction (ED) trial, mean blood testosterone was numerically higher after three months but not statistically different from baseline. A 2012 case report described elevated DHT that fell after stopping a local capsule. No controlled human study has demonstrated a reproducible, clinically meaningful rise in total or free testosterone as a primary endpoint. Half-life, tissue distribution, and human metabolic pathways (e.g., specific cytochrome P450 enzymes) for *B. superba* extracts as a whole are not established; isoflavone constituents are generally subject to gut-microbial conversion and hepatic conjugation, with relatively short plasma half-lives on the order of hours. ## Historical Context & Evolution *Butea superba* (Red Kwao Krua / Red Kwao Khruea) has long been used in Thai folk practice as a male rejuvenative and sexual-vigor tonic, distinguished from white Kwao Krua (*Pueraria mirifica*, used mainly as a phytoestrogen — a plant-derived compound that can act like estrogen — for women) and black Kwao Krua (historically *Mucuna* species). Indian traditional use of related *Butea* material has emphasized astringent gum and other non-sexual indications more than male potency. Modern interest accelerated in the early 2000s after isolation of flavonoids with phosphodiesterase-inhibitory activity and after Cherdshewasart and Nimsakul published the 2003 double-blind ED trial in *Asian Journal of Andrology*. Subsequent animal programs mapped androgen-like accessory-organ effects, high-dose testosterone suppression, genotoxicity (DNA-damage toxicity) signals at extreme doses, and mixed estrogenic/anti-estrogenic profiles. The 2010 Cortés-González comparison with sildenafil then showed that a commercial product’s apparent superiority was not reproducible and was linked by the supplier to PDE5-inhibitor adulteration — shifting scientific caution toward product authenticity rather than pure botanical efficacy. The herb remains available as an over-the-counter dietary-supplement root powder or extract, especially in Thailand and online markets, while high-quality placebo-controlled human data on testosterone as a primary outcome are still absent. ## Expected Benefits ### Low 🟩 #### Improved Erectile Function Scores in Men with Mild–Moderate ED In a three-month randomized double-blind trial in Thai men with erectile dysfunction (ages ~30–70), crude dried tuber powder (250 mg capsules; up to four capsules daily after a short run-in) improved four of five IIEF-5 domains, and 82.4% of treated participants reported noticeable improvement on sexual records, without significant laboratory toxicity. Haematology and chemistry, including testosterone, were stable. The evidence grade is limited by small sample size, a single geographic population, incomplete placebo retention (all placebo participants reportedly discontinued), and lack of replication with independently verified botanical material. A later commercial-product study could not confirm benefit after batch change and adulteration disclosure. **Magnitude:** About 82% of treated men reported noticeable erectile improvement in the 2003 trial; absolute IIEF-5 score deltas are incompletely reported in secondary sources. #### Accessory Sex-Organ Support Requiring Endogenous Testosterone (Preclinical) In intact male rats, oral *B. superba* at 250 mg/kg increased seminal vesicle weight without raising serum testosterone, LH, or FSH, while high-dose testosterone propionate produced classic androgenic organ growth plus LH/FSH suppression. In orchidectomized animals the herb reduced LH without restoring organ weights, supporting a model of weak peripheral androgen-like activity that depends on residual endogenous testosterone rather than new testosterone production from scratch. **Magnitude:** Seminal vesicle weight increase observed only at the highest tested intact-male dose (250 mg/kg); no human organ-level endpoint exists. #### Sperm Count / Motility Signals from Isolated Isoflavones (Preclinical) Daidzein and genistein isolated from *B. superba*, alone and especially in combination, raised sperm number, motility, cholesterol, and testosterone in male mice relative to controls, with a reported synergistic effect of the combination. Whole-plant powder at a very high dose (1,250 mg/kg) increased rat sperm count by about 16% versus control in an eight-week study, with no major organ toxicity at 250 mg/kg. **Magnitude:** ~16% higher sperm count versus control at 1,250 mg/kg whole powder in rats; mouse isoflavone work showed statistically significant multi-parameter gains without human confirmation. ### Speculative 🟨 #### Elevation of Circulating Androgens (Testosterone or DHT) in Humans ⚠️ Conflicted Marketing and traditional use imply a testosterone-raising effect, but controlled human data do not support this as a reliable outcome: the 2003 ED trial found no significant change in blood testosterone (pre 2.75 ± 1.40 vs post 3.06 ± 1.37 in reported units). A single 2012 case report described elevated DHT that normalized within a week of stopping a local capsule. Animal data conflict: high-dose subchronic rat powder lowered serum testosterone, a separate two-week whole-extract rat study reported a serum testosterone increase, and mouse work with isolated genistein/daidzein is not equivalent to whole-root human products. Basis is therefore mechanistic, anecdotal, and conflicted animal data only — not controlled human endocrine trials with testosterone as primary endpoint. ## Benefit-Modifying Factors * **Baseline erectile dysfunction severity:** The sole positive human trial enrolled men with clinical ED; benefit on erectile scores may not translate to eugonadal men (those with normal gonadal hormone production) seeking a pure increase in testosterone without ED. * **Baseline androgen status:** Preclinical data suggest accessory-organ effects depend on endogenous testosterone; men with very low baseline testosterone or suppressed gonadotropins (LH and FSH, the pituitary hormones that drive testicular function) may see less peripheral androgen-like response, while a single case of high DHT occurred in an otherwise healthy adult. * **Sex:** Traditional and clinical use is almost exclusively male. Female-rat data show uterine growth and anti-estrogenic LH effects; intentional use for testosterone goals in women is outside the studied population and raises theoretical hyperandrogenism (excess male-hormone) concerns. * **Age:** Human volunteers were 30–70 years; older men with vascular ED may be the most relevant group for erectile endpoints, but age-stratified testosterone responses are unknown. * **Product authenticity and dose:** Benefits claimed for commercial products are undermined when PDE5 adulterants are present; batch-to-batch botanical content (isoflavone profile by region, e.g., Phrae root core vs bark) also varies in animal erectile assays. * **Genetic polymorphisms:** No human pharmacogenetic data exist for *B. superba*. Isoflavone metabolism can vary with gut microbiota and phase-II conjugation enzymes, but specific variants (e.g., affecting daidzein-to-equol conversion — equol is a gut-microbial metabolite of daidzein) have not been studied for this herb. ## Potential Risks & Side Effects ### Medium 🟥 🟥 #### Product Adulteration with Undeclared PDE5 Inhibitors In a 32-man comparative study, a commercial *B. superba* product improved IIEF-5 similarly to sildenafil 50 mg in an open-label phase, but a second batch showed no effect under double-blind conditions. The supplier’s analysis indicated the first preparation had been blended with a phosphodiesterase-5 inhibitor. Adulterated sexual-enhancement products that list *B. superba* among ingredients have also appeared in U.S. Food and Drug Administration (FDA)–linked ConsumerLab recall notices. Clinical consequences of undeclared PDE5 drugs include dangerous blood-pressure drops when combined with nitrates, and unpredictable dosing. **Magnitude:** In the 2010 study, open-label “response” rates were ~84% for the first batch versus ~81% for sildenafil; the second authentic-appearing batch produced no effect. ### Low 🟥 #### High-Dose Androgen Suppression and Liver Enzyme Elevation (Animal) Ninety-day oral administration of tuber powder at 150–200 mg/kg/day in male rats reduced serum testosterone dose-dependently, raised alkaline phosphatase (ALP) and aspartate aminotransferase (AST) at 150 mg/kg, and altered neutrophil/eosinophil counts and creatinine at 200 mg/kg. These doses greatly exceed traditional human gram-or-less intakes when scaled, but establish a toxicity ceiling and argue against “more is better” for a testosterone goal. **Magnitude:** Dose-dependent testosterone decrease at 150 and 200 mg/kg/day in rats; human equivalent margins depend on scaling method but imply multi-gram excess relative to ~0.5–1 g/day traditional use. #### Genotoxicity Signal at Extreme Doses (Animal) Micronucleus testing showed increased micronucleated polychromatic erythrocytes (immature red blood cells with small extra nuclei, a DNA-damage marker) at 1,000 mg/kg/day aqueous powder for nine weeks in rats; a separate micronucleus assay found acute micronucleus induction at 300 mg/kg plant extract (about 16 g/kg plant powder equivalent). Ames testing (a standard bacterial assay for DNA-mutation risk) of extract was non-mutagenic and even antimutagenic at lower concentrations. Dominant-lethal reproductive toxicity (a breeding assay for heritable germ-cell damage) was not seen at the tested powder doses. **Magnitude:** Positive micronucleus signal at ~300–1,000 mg/kg extract/powder ranges in rodents; human traditional doses are far lower. #### Case-Level Hyperandrogenemia (Elevated DHT) One healthy 35-year-old man developed increased sexual drive and elevated DHT (1,512 pg/mL; reference 250–990) after weeks of a local *B. superba* capsule for hair loss; DHT and symptoms normalized within one week of stopping. Free testosterone percentage and sex hormone-binding globulin (SHBG, a blood protein that binds sex hormones) were reported; total testosterone trajectory was not fully detailed. Causal attribution is plausible but uncontrolled. **Magnitude:** Single case; DHT roughly 1.5× the upper reference limit, reversible in ~1 week. ### Speculative 🟨 #### Estrogenic / Anti-Estrogenic Tissue Effects and Hormone-Sensitive Conditions Extracts show weak estrogen-receptor activity and anti-estrogenic profiles in vitro and can stimulate or remodel uterine tissue in female rats. Theoretical concern exists for individuals with hormone-sensitive cancers or conditions, though human incidence data are absent and MCF-7 work showed anti-proliferative rather than proliferative effects for *B. superba* relative to *P. mirifica*. #### Unknown Long-Term Human Safety No multi-year human cohort or large post-marketing safety database exists for continuous *B. superba* use aimed at testosterone optimization. Human exposures in published work are short (weeks to about three months), so delayed hepatic, reproductive, or genotoxic signals cannot be excluded from clinical data alone. The concern rests on the absence of long-duration surveillance rather than on a documented chronic syndrome; animal high-dose findings supply only indirect upper-bound context. ## Risk-Modifying Factors * **Dose:** Animal liver-enzyme, hematologic, testosterone-suppressive, and genotoxic findings cluster at high mg/kg exposures; staying near studied human capsule totals (~0.5–1 g/day crude powder equivalent) is the main practical mitigator. * **Product quality:** Multi-herb “male enhancement” formulas that list *B. superba* have a documented adulteration history; third-party testing for identity and for undeclared PDE5 drugs (sildenafil, tadalafil, and analogues) reduces this risk more than brand claims alone. * **Sex and pregnancy:** Female reproductive-tract stimulation in rats and absence of human female safety data make use in women — especially pregnancy or planned conception — a high-uncertainty zone. * **Pre-existing liver disease:** High-dose rat ALP/AST elevations suggest caution when baseline liver enzymes are already abnormal. * **Age:** Older adults may have more polypharmacy (use of multiple concurrent medications, such as nitrates and antihypertensives) that interact catastrophically with adulterant PDE5 drugs even if the botanical itself is mild. * **Genetic factors:** No specific risk-modifying polymorphisms are established for *B. superba*. ## Key Interactions & Contraindications * **Nitrates and nitric-oxide donors (nitroglycerin, isosorbide mononitrate/dinitrate, amyl nitrite):** Severity — absolute contraindication if the product is adulterated with a PDE5 inhibitor (or if PDE5-like activity is clinically relevant). Consequence — severe hypotension (dangerously low blood pressure), syncope (fainting), myocardial ischemia (reduced blood flow to heart muscle). Mitigation — concurrent use is not supported; identity-tested products only, and nitrates remain incompatible if any PDE5 activity is suspected. * **Prescription PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil):** Severity — caution / avoid concurrent use. Consequence — additive vasodilation (blood-vessel widening), headache, hypotension. Mitigation — intentional PDE5 drugs are not combined with untested *B. superba* products in studied practice. * **Antihypertensives (e.g., amlodipine, lisinopril, losartan):** Severity — caution if adulterated or if vascular effects add. Consequence — excessive blood-pressure reduction. Mitigation — monitor blood pressure if used together. * **Hormone therapies (testosterone replacement, anti-androgens (drugs that block male-hormone action), aromatase inhibitors (drugs that block conversion of testosterone to estrogen), estrogen therapies):** Severity — caution. Consequence — unpredictable HPG-axis feedback or androgen metabolite shifts (case-level DHT rise; high-dose animal testosterone (T) suppression). Mitigation — coordinate labs (total/free T, DHT, LH, FSH, estradiol) rather than combining multiple hormone-active agents without laboratory follow-up. * **Other multi-herb sexual-enhancer products marketed as testosterone supports (Tribulus, tongkat ali, yohimbine, high-dose fenugreek, etc.):** Severity — caution. Consequence — confounded effects, higher adulteration risk in proprietary blends. Mitigation — single-ingredient, tested products are the usual basis when evaluating *B. superba* itself. * **Over-the-counter antiplatelets and nonsteroidal anti-inflammatory drugs (NSAIDs; aspirin, ibuprofen, naproxen):** Severity — theoretical / monitor. Consequence — unknown additive bleeding or platelet effects if *B. superba* isoflavones affect platelet pathways as reported for some related plants; no controlled interaction data. Mitigation — no specific dose adjustment established; watch for unusual bruising or bleeding if combined. * **Anticoagulants / antiplatelets (warfarin, aspirin, clopidogrel):** Severity — theoretical / monitor. Consequence — unknown; isoflavones occasionally affect platelet pathways in other plants. Mitigation — no specific dose adjustment established; watch for bleeding signals. * **Populations to avoid or use only with specialist oversight:** Women who are pregnant, breastfeeding, or seeking fertility care; individuals with active hormone-sensitive malignancy; anyone using organic nitrates; people unwilling to obtain identity/adulteration testing for sexual-enhancement supplements; children and adolescents. ## Risk Mitigation Strategies * **Identity and adulteration testing:** Products with third-party certificates of analysis that confirm *Butea superba* root/tuber identity (ideally DNA or chromatographic fingerprint) and that screen for sildenafil, tadalafil, and common analogues directly mitigate the documented PDE5-adulteration risk. * **Dose ceiling near clinical trial totals:** Crude powder or labeled root extract in the approximate range studied for ED (on the order of 500–1,000 mg/day of 250 mg capsules), rather than multi-gram loading doses, reduces extrapolation toward animal toxicity and genotoxicity exposures. * **Baseline and follow-up hormone and liver panels:** Morning total and free testosterone, SHBG, DHT, LH, FSH, estradiol, complete blood count (CBC), and comprehensive metabolic panel (CMP, including AST, alanine aminotransferase (ALT), and ALP) before first use and after 4–12 weeks detect both the rare hyperandrogenemia pattern and high-dose hepatic signals. * **Nitrate co-use and untested multi-ingredient products:** Concurrent use with prescription or recreational nitrates is incompatible with PDE5 risk; multi-ingredient “male enhancement” capsules confound evaluation of *B. superba* itself. * **Time-limited trial with stop rules:** An 8–12 week evaluation window with pre-specified stop criteria (abnormal liver enzymes, abnormal DHT/T rise or fall, blood-pressure symptoms) limits cumulative unknown long-term exposure. * **Single-ingredient first:** Assessing response with *B. superba* alone keeps erectile or lab changes from being attributed to co-ingested yohimbine, stimulants, or hidden drugs. ## Therapeutic Protocol * **Studied human preparation (ED trial):** Dried tuberous root powder in 250 mg capsules; twice daily for the first four days, then up to four capsules daily (about 1 g/day) for the remainder of a three-month course in the Cherdshewasart & Nimsakul design. * **Traditional / Examine-cited range:** Rough traditional and secondary sources often cite about 100–250 mg of preparation, or up to the gram-scale powder totals above; standardized extract labels vary and lack a consensus isoflavone marker standard for “testosterone” use. * **Timing:** The 2010 commercial-product study instructed 100 mg about 1–2 hours before sexual activity for acute erectile intent; daily divided dosing was used in the 2003 chronic trial. For an endocrine experiment, consistent morning dosing with food is a practical default given unknown kinetics. * **Half-life and split dosing:** Human pharmacokinetic half-life of whole extract is not published; isoflavone constituents generally clear over hours, so once- or twice-daily split dosing is reasonable if stomach tolerance requires it. * **Competing approaches:** (1) Traditional crude Thai tuber powder as in the 2003 randomized controlled trial (RCT); (2) commercial “extract” capsules sold for male enhancement — higher adulteration risk; (3) isolated soy-type isoflavones are not equivalent substitutes even though genistein/daidzein occur in the plant. No major Western longevity-clinic protocol (e.g., Attia-style) standardizes *B. superba* for testosterone. * **Genetics:** No dose-adjustment algorithm by APOE (apolipoprotein E lipid-transport gene variants), MTHFR (methylenetetrahydrofolate reductase, a folate-metabolism enzyme gene), COMT (catechol-O-methyltransferase, a catecholamine-metabolizing enzyme gene), or androgen-receptor CAG repeats (variable DNA sequence length in the androgen receptor gene) exists for this herb. * **Sex differences:** Protocols and trials are male-oriented; female dosing for testosterone goals is not established. * **Age:** Older men with vascular ED match the trial population better than young eugonadal adults seeking above-normal testosterone. * **Baseline biomarkers:** Morning hypogonadal (clinically low or low-normal gonadal hormone production) or low-normal labs are the usual starting context when the goal is testosterone improvement; *B. superba* is a weak and inconsistent endocrine intervention compared with addressing sleep, body composition, and — where indicated — medical testosterone therapy under clinician care. * **Pre-existing conditions:** Active liver disease, nitrate use, unstable cardiovascular disease, or hormone-sensitive cancer history are contexts in which untested sexual-enhancement botanicals are not part of studied protocols. ## Discontinuation & Cycling * **Duration intent:** Studied human use was finite (about three months for ED), not lifelong hormone replacement. For a testosterone-focused experiment, an 8–12 week block with labs is a rational frame. * **Withdrawal:** No classic withdrawal syndrome is described. The hyperandrogenemia case normalized DHT and libido within about one week of stopping, suggesting rapid offset of that signal. * **Tapering:** Not required on pharmacologic grounds at traditional doses; simple cessation is typical. * **Cycling:** No evidence that cycling preserves efficacy. If used, separate courses with lab reassessment avoid continuous unknown exposure and allow detection of delayed liver or hormone changes. * **After stopping adulterated products:** When PDE5-like effects occurred with a labeled product, subsequent batches remain untrusted for identity purposes until tested, regardless of label. ## Sourcing and Quality * **Plant part:** Tuberous root / root core is the ethnomedical and experimental material; bark and other parts differ in animal erectile potency. * **Identity:** Latin binomial *Butea superba* Roxb. on the label improves identity confidence; confusion with *Butea monosperma* or with white/black Kwao Krua species is a known ethnobotanical issue — DNA barcode or chromatographic methods used in Thai herbal pharmacopeia work further reduce misidentification risk. * **Adulteration screen:** Third-party tests for undeclared sildenafil, tadalafil, and analogues are more important for this category than for most herbals. * **Standardization:** No universally accepted “percent flavonoid” or marker compound is validated against human testosterone outcomes; Examine notes the primary androgenic bioactives remain unidentified. Standardization claims function as quality signals rather than proof of endocrine efficacy. * **Form:** Capsules of dried powder match the 2003 trial; ethanolic extracts dominate animal erection work. Proprietary multi-herb products marketed for testosterone support confound evaluation when the question is *B. superba* itself. * **Reputable sourcing patterns:** Thai-origin single-ingredient root products with batch certificates of analysis (COAs) are the pattern associated with clearer identity; anonymous marketplace multi-ingredient “male enhancement” products repeatedly tied to FDA warnings are the usual high-uncertainty sources. ## Practical Considerations * **Time to effect:** Erectile questionnaire changes in the 2003 trial were assessed over a three-month course; acute pre-sexual dosing was tried in the 2010 product study. Any hormone lab change would be expected on a weeks-to-months timescale if it occurs at all — and the best human data show no significant mean testosterone shift. * **Common pitfalls:** Expecting a robust testosterone increase comparable to medical therapy; using untested multi-ingredient sexual enhancers; escalating dose into multi-gram ranges based on animal mg/kg figures; ignoring nitrate and PDE5 interaction risk from adulterants; combining with other unproven multi-herb sexual-enhancer products and attributing any lab noise to *B. superba*. * **Regulatory status:** Sold as a dietary supplement / traditional herb in many markets, not as an FDA-approved drug for hypogonadism (clinically low testosterone production or levels) or ED. Claims to diagnose, treat, or cure disease are outside lawful supplement labeling in the U.S. * **Cost and access:** Single-ingredient root capsules are generally inexpensive relative to prescription testosterone monitoring programs; the larger “cost” is analytic testing and clinical labs if used seriously. ## Interaction with Foundational Habits * **Sleep:** Direction — none established for the herb itself (no direct evidence that *B. superba* improves or impairs sleep architecture). Sleep restriction itself lowers testosterone; any botanical experiment is confounded if sleep debt remains unaddressed. * **Nutrition:** Direction — indirect / none dominant at traditional doses. Isoflavone-containing herbs interact with overall phytoestrogen intake; extreme soy restriction or excess is unlikely to dominate at traditional *B. superba* doses. Energy availability and body-fat extremes have larger, proven effects on the HPG axis than this herb. * **Exercise:** Direction — none established for blunting or potentiating training adaptations; no data show the herb blunts hypertrophy. Resistance training and adequate recovery raise or preserve testosterone more reliably than *B. superba* in the evidence hierarchy. Erectile vascular effects are theoretically compatible with training but unstudied in athletes. * **Stress management:** Direction — none established in humans for cortisol or stress-axis modulation (*B. superba* is not a validated cortisol-modulating adaptogen — a stress-support herb — in human trials). Chronic psychological stress elevates cortisol and can suppress gonadotropins. Animal antidepressant-like findings exist but are outside the testosterone indication. ## Monitoring Protocol & Defining Success Baseline testing before a time-limited trial, then repeat at a defined interval (e.g., 4 weeks and 12 weeks), provides the only objective readout for a testosterone-focused use case. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | Total testosterone (morning) | Often ~500–900+ ng/dL in optimization-oriented practice (lab-specific) | Primary goal marker for this review | Draw 7–10 a.m.; repeat on same lab; conventional “normal” lower bound is often ~264–300 ng/dL — functional targets are higher and individualized | | Free testosterone | Lab- and method-specific; aim mid–upper functional band | Bioavailable androgen fraction | Pair with SHBG; equilibrium dialysis (lab method that physically separates unbound hormone) preferred when available | | SHBG | Roughly mid-reference (lab-specific) | Interprets free vs total T | Affected by thyroid, insulin resistance, estrogen | | DHT | Within lab reference (case report used 250–990 pg/mL) | Detects the hyperandrogenemia pattern in the case report | Recheck if libido surges or androgenic skin/hair changes appear | | LH | Mid-reference | Distinguishes primary vs secondary patterns | High-dose animal data lowered T without LH rise | | FSH | Mid-reference | Sperm-line and gonadotropin context | Relevant if fertility is a concurrent goal | | Estradiol (sensitive) | Men: often ~20–30 pg/mL functional discussion range | Aromatization (conversion of testosterone to estrogen) and symptom balance | Use LC-MS/MS (liquid chromatography–tandem mass spectrometry) when possible | | AST / ALT / ALP | Within lab reference; investigate any rise | High-dose rat hepatotoxicity signal | Fasting not required for enzymes alone | | CBC | Within reference | High-dose rat neutrophil/eosinophil shifts | Baseline safety | | Fasting glucose / lipids | Per metabolic goals | General cardiometabolic context for ED | ED and metabolic disease often coexist | Baseline labs are obtained before the first dose so that any later testosterone, DHT, or liver-enzyme change has a personal control. Ongoing monitoring at approximately 4 weeks and again at 8–12 weeks (or at symptom change) is a practical cadence for a short trial; longer continuous use lacks an evidence-based schedule. **Qualitative markers** * Morning energy and motivation * Libido and sexual confidence * Erectile rigidity and consistency (if ED is present) * Sleep quality and recovery from training * Androgenic skin or hair changes (acne, accelerated scalp hair loss) that might track DHT * Headache, flushing, or blood-pressure symptoms that could signal PDE5-like adulteration ## Emerging Research * **No registered interventional trials:** A ClinicalTrials.gov search for *Butea superba* as intervention returned no matching studies as of this review’s creation date — future human testosterone RCTs, if any, are not yet publicly registered under this name. * **Adulteration forensics:** The Cortés-González et al., 2010 finding ([PMID 19624593](https://pubmed.ncbi.nlm.nih.gov/19624593/)) continues to motivate analytical methods for PDE5 analogues in products labeled with Thai male herbs; further market surveillance could either rehabilitate or further undermine commercial claims. * **Isoflavone synergy:** Mouse data from Eumkeb et al., 2017 that daidzein plus genistein raise testosterone and sperm metrics ([PMID 27125688](https://pubmed.ncbi.nlm.nih.gov/27125688/)) invite human pharmacokinetic and dose-finding work — such trials could strengthen or refute a pure-endocrine rationale. * **High-dose endocrine disruption:** Subchronic rat testosterone suppression reported by Cherdshewasart et al., 2008 ([PMID 18554827](https://pubmed.ncbi.nlm.nih.gov/18554827/)) is a cautionary signal; human dose-ranging with intensive hormone panels would clarify the margin between traditional use and HPG suppression. * **Cognitive and antioxidant extensions:** Separate rodent work by Sirichaiwetchakoon et al., 2021 on scopolamine-related memory ([PMID 34671404](https://pubmed.ncbi.nlm.nih.gov/34671404/)) and Sirichaiwetchakoon & Eumkeb, 2024 on isolated-human low-density lipoprotein (LDL) oxidation ([PMID 38310207](https://pubmed.ncbi.nlm.nih.gov/38310207/)) is mechanistically interesting but does not repair the testosterone evidence gap. ## Conclusion *Butea superba* is a traditional Thai tuberous-root herb used for male vitality and erectile support. Its best human evidence is a small randomized trial showing improved erectile-function scores over three months without a clear rise in blood testosterone. A later commercial-product comparison with sildenafil could not be replicated and was linked to undeclared erectile-dysfunction drug adulteration, which lowers confidence in many marketplace claims. Animal research paints a mixed hormone picture: weak male-hormone–like effects on sex-related glands at some doses, testosterone *reduction* and liver-enzyme stress at high doses, and testosterone/sperm gains from isolated plant compounds in mice that do not automatically translate to whole-root human use. A single case report of elevated levels of a potent testosterone byproduct after local capsule use remains the clearest human male-hormone signal and reversed quickly after stopping. For adults focused on optimizing testosterone rather than treating erectile symptoms alone, the evidence does not establish *Butea superba* as a reliable testosterone-raising intervention. Product identity testing, conservative dosing near studied capsule totals, and paired hormone and liver monitoring define a cautious experimental frame if the herb is still considered. Foundational levers — sleep, body composition, resistance training, and, where appropriate, medical care for true low testosterone — rest on far stronger evidence than this botanical. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**